Suppr超能文献

肾上腺原发性恶性肿瘤。

Primary malignant tumors of the adrenal glands.

作者信息

Almeida Madson Q, Bezerra-Neto Joao Evangelista, Mendonça Berenice B, Latronico Ana Claudia, Fragoso Maria Candida B V

机构信息

Unidade de Suprarrenal, Laboratorio de Hormonios e Genetica Molecular LIM/42, Servico de Endocrinologia e Metabologia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.

Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.

出版信息

Clinics (Sao Paulo). 2018 Dec 10;73(suppl 1):e756s. doi: 10.6061/clinics/2018/e756s.

Abstract

Malignancy must be considered in the management of adrenal lesions, including those incidentally identified on imaging studies. Adrenocortical carcinomas (ACCs) are rare tumors with an estimated annual incidence of 0.7-2 cases per year and a worldwide prevalence of 4-12 cases per million/year. However, a much higher incidence of these tumors (>15 times) has been demonstrated in south and southeastern Brazil. Most ACCs cause hypersecretion of steroids including glucocorticoids and androgens. ACC patients have a very poor prognosis with a 5-year overall survival (OS) below 30% in most series. Pheochromocytoma or paraganglioma (PPGL) is a metabolically active tumor originating from the chromaffin cells of the adrenal medulla. The incidence of PPGL is 0.2 to 0.9 cases per 100,000 individuals per year. Pheochromocytomas are present in approximately 4-7% of patients with adrenal incidentalomas. Classically, PPGL manifests as paroxysmal attacks of the following 4 symptoms: headaches, diaphoresis, palpitations, and severe hypertensive episodes. The diagnosis of malignant PPGL relies on the presence of local invasion or metastasis. In this review, we present the clinical and biochemical characteristics and pathogenesis of malignant primary lesions that affect the cortex and medulla of human adrenal glands.

摘要

在肾上腺病变的管理中必须考虑恶性肿瘤,包括那些在影像学检查中偶然发现的病变。肾上腺皮质癌(ACC)是罕见肿瘤,估计年发病率为每年0.7 - 2例,全球患病率为每百万/年4 - 12例。然而,在巴西南部和东南部,这些肿瘤的发病率要高得多(超过15倍)。大多数ACC会导致类固醇分泌过多,包括糖皮质激素和雄激素。ACC患者预后很差,在大多数系列研究中,5年总生存率低于30%。嗜铬细胞瘤或副神经节瘤(PPGL)是一种起源于肾上腺髓质嗜铬细胞的代谢活跃肿瘤。PPGL的发病率为每年每10万人0.2至0.9例。肾上腺偶发瘤患者中约4 - 7%存在嗜铬细胞瘤。典型情况下,PPGL表现为以下4种症状的阵发性发作:头痛、多汗、心悸和严重高血压发作。恶性PPGL的诊断依赖于局部侵犯或转移的存在。在本综述中,我们介绍了影响人类肾上腺皮质和髓质的恶性原发性病变的临床、生化特征及发病机制。

相似文献

1
Primary malignant tumors of the adrenal glands.
Clinics (Sao Paulo). 2018 Dec 10;73(suppl 1):e756s. doi: 10.6061/clinics/2018/e756s.
3
Clinical management of malignant adrenal tumors.
J Cancer Res Clin Oncol. 2001;127(3):143-55. doi: 10.1007/s004320000170.
4
Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management.
Curr Opin Endocrinol Diabetes Obes. 2019 Jun;26(3):146-154. doi: 10.1097/MED.0000000000000476.
5
[Malignant tumors of the adrenal: contribution to the repository CCAFU INCa].
Prog Urol. 2010 Nov;20 Suppl 4:S310-6. doi: 10.1016/S1166-7087(10)70047-6.
6
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2012 Oct;23 Suppl 7:vii131-8. doi: 10.1093/annonc/mds231.
7
Management of adrenocortical carcinoma.
J Natl Compr Canc Netw. 2009 Jul;7(7):752-8; quiz 759. doi: 10.6004/jnccn.2009.0051.
9
Malignant adrenal tumors.
Semin Pediatr Surg. 2006 Feb;15(1):48-56. doi: 10.1053/j.sempedsurg.2005.11.008.
10
Rare adrenal tumors in children.
Semin Pediatr Surg. 2014 Apr;23(2):71-5. doi: 10.1053/j.sempedsurg.2014.03.004. Epub 2014 Mar 14.

引用本文的文献

2
Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment.
Front Endocrinol (Lausanne). 2024 Dec 13;15:1433582. doi: 10.3389/fendo.2024.1433582. eCollection 2024.
7
The Spectrum of Postoperative Complications and Outcomes After Open Adrenalectomy: An Experience From a Developing Country.
Cureus. 2022 Nov 11;14(11):e31357. doi: 10.7759/cureus.31357. eCollection 2022 Nov.
10
Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors.
J Clin Med. 2022 Sep 22;11(19):5563. doi: 10.3390/jcm11195563.

本文引用的文献

2
Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Ann Surg Oncol. 2017 Nov;24(12):3624-3630. doi: 10.1245/s10434-017-6074-1. Epub 2017 Sep 7.
3
Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: Are we offering the best?
Int Braz J Urol. 2017 Sep-Oct;43(5):841-848. doi: 10.1590/S1677-5538.IBJU.2017.0095.
4
Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3296-3305. doi: 10.1210/jc.2017-00992.
5
PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.
J Mol Diagn. 2017 Jul;19(4):575-588. doi: 10.1016/j.jmoldx.2017.04.009. Epub 2017 May 25.
7
Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1122-1132. doi: 10.1210/jc.2016-3829.
8
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.
Cancer Cell. 2017 Feb 13;31(2):181-193. doi: 10.1016/j.ccell.2017.01.001. Epub 2017 Feb 2.
10
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.
Horm Cancer. 2016 Feb;7(1):29-35. doi: 10.1007/s12672-015-0241-2. Epub 2016 Jan 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验